Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

iprofloxacin against B. anthracis, despite a less than optimal dose.  Solithromycin also delayed mortality in mice for days after dosing against F. tularensis.  Future studies will evaluate optimal doses of solithromycin based on PK/PD modeling and the current therapeutic regimen being tested in Phase 2.  

"Solithromycin is emerging as a very promising broad spectrum, well-tolerated antibiotic," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals.  "Pre-clinical and clinical data collected to date show it to have a broad activity spectrum and to be well tolerated in healthy volunteers.  Its flexibility of administration including once-daily oral, oral suspension and intravenous, its high tissue penetration, especially in blood and lung including lung macrophages, and its ability to target intracellular pathogens, demonstrate its significant potential for both civilian and bio-defense applications.  Building a safety and efficacy database for civilian bacterial pneumonia coupled with meeting the animal rule, which is a unique regulatory mechanism to gain FDA approval based on animal data when well-controlled efficacy studies in humans is not ethical or feasible, could be a path forward for approval for bio-defense indications."

About solithromycin (CEM-101)Solithromycin is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products:

  • 8 to 16 times more potent than azithromycin and is active against organisms that have become resistant to azithromycin
  • Potent in vitro activity against all important respiratory pathogens, including pneumococci, beta-hemolytic streptococci, staphylococci, Hemophilus, Legionella, Mycoplasma, Moraxella and Chlamydophila
  • Potent in vitro activity against other medically significant pathogens including CA-MRSA, M. avium, malaria, enteroc
    '/>"/>

  • SOURCE Cempra Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
    2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
    3. Savient Pharmaceuticals Provides Business Update
    4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
    7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
    9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
    10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ... Company,s lead antibody, HuMab 5B1, will be garnering major ... the upcoming World Molecular Imaging Congress (WMIC) being held ... Researchers from the Department of Radiology at Memorial Sloan ... use of MabVax,s lead antibody as a PET imaging ...
    (Date:8/31/2015)... , Aug. 31, 2015  For people with ... brighten their day. The biotechnology company, located in the ... one of the best potential therapies yet for people ... entitled, " Correction of Down syndrome and Edwards syndrome ... journal DNA Research . Elixirgen plans to develop ...
    (Date:8/31/2015)... Calif. , Aug. 31, 2015 FLX ... and development of novel cancer immunotherapies, announced today that ... as Chief Executive Officer and William Ho , ... Ho join an experienced management team led by veterans ... Fridman , Ph.D., Chief Scientific Officer; Jay Powers ...
    (Date:8/31/2015)... , ... August 31, 2015 , ... There’s a new ... Minerva is the first commercially available new FDA approved system in the last 14 ... of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction ...
    Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
    ... ... Parkinson,s disease patients. Daniel Neal from Palm Springs, CA, gains the ability and confidence to ... ... portable device improves walking for Parkinson,s disease patients. Daniel Neal from Palm Springs, CA, gains ...
    ... LYNBROOK, N.Y., Sept. 11 BioSpecifics Technologies Corp. (Nasdaq: ... class collagenase-based products, today announced that BioSpecifics, President, Tom Wegman, ... Industry" Conference on Wednesday, September 16, 2009, at 9:00 am ... New York, NY. , , A live ...
    ... ... to demonstrate the power of nanotechnology based regenerative medicines. , ... (PRWEB) September 11, 2009 -- Long-time financier ... to rejuvenate living animals with advanced nanotechnologies developed by his labs. The goal of ...
    Cached Biology Technology:New Superman Glasses for Parkinson's Disease Improve Walking and Quality of Life 2Matthew Sarad to Reverse Aging and Cure Cancer 2Matthew Sarad to Reverse Aging and Cure Cancer 3Matthew Sarad to Reverse Aging and Cure Cancer 4
    (Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
    (Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
    (Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
    Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
    ... years ago, the understory of late Mesozoic forests was dominated ... Today, only one genus from this group, Equisetum ... a prime candidate for being the oldest extant genus of ... the evolutionary beginnings of the genus Equisetum . Molecular ...
    ... The ability to use nanoparticles to deliver payloads of ... a fundamental change in chemotherapy treatment. But scientists are ... of this technology. Although developing nanoparticles ... while sparing normal, healthy tissues is still the ...
    ... from the Howard Hughes Medical Institute (HHMI)will be used ... to enable thousands of college and university science faculty ... biology education. The $3 million grant will expand ... Biology from a single location at the University of ...
    Cached Biology News:Newly discovered plant fossil reveals more than age 2Newly discovered plant fossil reveals more than age 3Newly discovered plant fossil reveals more than age 4Hitting target in cancer fight now easier with new nanoparticle platform, UCLA scientists say 2HHMI helps summer institute expand to regional sites 2HHMI helps summer institute expand to regional sites 3HHMI helps summer institute expand to regional sites 4
    Contains L-glutamine...
    ... The PhosphatidylEthanolamine-Binding Protein (PEBP) does ... serine protease inhibitors. PEBP is ... spleen, testis, ovary, muscle, and stomach. ... involved in is exerting inhibitory activity ...
    ...
    Highly sensive assay for detecting apoptosis in living cells. See detailed descriptions above in K250-25....
    Biology Products: